Benefits, Risks of Darbepoetin Alfa in Diabetes Assessed

Use in those with chronic kidney disease and anemia did not reduce mortality or renal disease
By Andrea Mongler
HealthDay Reporter

MONDAY, Nov. 2 (HealthDay News) -- In patients with diabetes, chronic kidney disease and anemia, darbepoetin alfa does not reduce death, cardiovascular or renal events, and may be linked to an increased risk of stroke, according to a study published online Oct. 30 in the New England Journal of Medicine.

Marc A. Pfeffer, M.D., of Brigham and Women's Hospital in Boston, and colleagues randomly assigned 2,012 patients with diabetes, chronic kidney disease and anemia to darbepoetin alfa to achieve a 13 g per deciliter hemoglobin level and 2,026 patients to placebo, with rescue darbepoetin alfa administered for hemoglobin levels below 9 g per deciliter.

The researchers found that death or a cardiovascular event occurred in 632 patients administered darbepoetin alfa and 602 patients on placebo (hazard ratio, 1.05), while death or end-stage renal disease occurred in 652 patients on darbepoetin alfa and 618 on placebo (hazard ratio, 1.06). Stroke occurred in 101 patients on darbepoetin alfa and 53 on placebo (hazard ratio, 1.92). In addition, the researchers observed only a modest improvement in patient-reported fatigue in the darbepoetin alfa group.

"It is our view that, in many patients with diabetes, chronic kidney disease, and moderate anemia who are not undergoing dialysis, the increased risk of stroke and possibly death among patients with a history of a malignant condition will outweigh any potential benefit of an erythropoiesis-stimulating agent," the authors conclude.

The study was supported by Amgen; several authors reported financial and consulting relationships with Amgen and other pharmaceutical companies.

Abstract
Full Text
Editorial

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Debunking Three Rape Myths
Journal of Forensic Nursing, October/December 2014
Expires: 12/31/2016 CE:2.5 $24.95


Drug updates and approvals: 2014 in review
The Nurse Practitioner, 13December 2014
Expires: 12/31/2016 CE:3 $27.95


Can Food Processing Enhance Cancer Protection?
Nutrition Today, September/October 2014
Expires: 10/31/2016 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events